Navigation Links
Zacks Releases Four Powerful ''Buy'' Stocks: Chemtura, Cardinal Health, HiTech Pharmacal and Gardner Denver
Date:12/30/2011

CHICAGO, Dec. 30, 2011 /PRNewswire/ -- Four free stock picks are being made available today on Zacks.com. The industry's leading independent research firm highlights one Zacks #1 Rank Strong Buy or a Zacks #2 Rank Buy stock for each of the four main styles of investing: Aggressive Growth, Growth & Income, Momentum, and Value.

(Logo:  http://photos.prnewswire.com/prnh/20101027/ZIRLOGO)

The four highlighted picks are: Chemtura Corporation (NYSE: CHMT), Cardinal Health, Inc. (NYSE: CAH), HiTech Pharmacal Co, Inc. (Nasdaq: HITK) and Gardner Denver, Inc. (NYSE: GDI).

Today, Zacks is promoting its ''Buy'' stock recommendations. Four daily picks are offered free. http://at.zacks.com/?id=88

From 1988 through the present – a period that included serious corrections and recessions – the Zacks #1 Rank Stocks have nearly tripled the market with a fully documented average gain of +28% per year.

Here is a summary of today's selected stocks that are now highly rated by Zacks:          

Aggressive Growth – Chemtura Corporation (NYSE: CHMT)

Chemtura Corporation analysts move earnings estimates higher.

Zacks Guide to Aggressive Growth Investing (free!) - http://at.zacks.com/?id=4309

Growth & Income – Cardinal Health, Inc. (NYSE: CAH)

Cardinal Health, Inc. carried its strong momentum into the first quarter of its fiscal 2012 and delivered its 9th consecutive positive earnings surprise. Analysts raised their estimates after the strong quarter for both 2012 and 2013, sending the stock to a Zacks #2 Rank (Buy).

Zacks Guide to Growth & Income Investing (free!) - http://at.zacks.com/?id=4310

Momentum – HiTech Pharmacal Co, Inc. (Nasdaq: HITK)

HiTech Pharmacal Co, Inc. just hit a new all-time high after reporting strong Q3 results that included an impressive 35% earnings surprise. With estimates on the rise and a high industry rank, this Zacks #1 rank stock is a solid pick for momentum.

Zacks Guide to Momentum Investing (free!):  http://at.zacks.com/?id=4311

Value – Gardner Denver, Inc. (NYSE: GDI)

Gardner Denver, Inc. is still on track for double digit earnings growth in 2012 after posting several record quarters in 2011. This Zacks #1 Rank (strong buy) has attractive valuations with a forward P/E of 13.8.

Zacks Guide to Value Investing (free!) -  http://at.zacks.com/?id=4312

How to Regularly Access Top Zacks Rank Picks for Free - http://at.zacks.com/?id=7154

Underlying the four free stock picks is a simple truth that first appeared in a Financial Analysts Journal article published in 1979. Leonard Zacks, a Ph.D. from M.I.T. found that "earnings estimate revisions are the most powerful force impacting stock prices."  Zacks #1 Rank is awarded to a stock when analysts sharply upgrade their estimates of what the company will earn.

Today, Zacks is promoting its stock recommendations by offering four daily picks free to those who register here: http://at.zacks.com/?id=7155

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Len Zacks. The company continually processes stock reports issued by 3,000 analysts from 150 brokerage firms.  It monitors more than 200,000 earnings estimates, looking for changes.

Then, when changes are discovered, they're applied to help assign more than 4,400 stocks into five Zacks Rank categories: #1 Strong Buy, #2 Buy, #3 Hold, #4 Sell, and #5 Strong Sell. This proprietary stock-picking system continues to outperform the market by a nearly 3-to-1 margin.

More Free Stock Picks

Each weekday, new Zacks #1 Rank or Zacks #2 Rank stock picks are released on the free email newsletter, Profit from the Pros. Investors are invited to register for their free subscription here: http://at.zacks.com/?id=91

Follow us on Twitter:  http://twitter.com/zacksresearch

Join us on Facebook:  http://www.facebook.com/ZacksInvestmentResearch

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.

Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
http://www.zacks.com

Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.


'/>"/>
SOURCE Zacks Investment Research, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Zacks Industry Outlook Highlights: Vertex Pharma, Human Genome Sciences, Biogen Idec and Perrigo
2. The Zacks Analyst Blog Highlights: Pfizer, Bristol - Myers Squibb, Eli Lilly, Forest Laboratories and Abbott Laboratories
3. Zacks Industry Outlook Highlights: Vertex Pharma, AstraZeneca, Abbott Labs, Allergan and Onyx Pharmaceuticals
4. Zacks Investment Research Initiates Coverage on Viral Genetics
5. Zacks Rates CardioGenics Outperform With Six-Month Target of $1.22
6. Medical Alarm Concepts Releases Initial Cut of New Television Commercial Scheduled for January Airing - Provides Investor Update
7. SuccessEHS Releases Patient-Centered Medical Home (PCMH) Toolkit
8. Talyst Releases AutoPharm Mobile
9. UHC Releases Reprocessing Guide for Value Analysis Program
10. TRACE Releases Report on Bribe Demands in the United States
11. Bupa International Releases Health Guides to Hong Kong and Singapore
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... and PITTSBURGH, Feb. 10, 2016 Mylan N.V. (NASDAQ, ... quarter and year ended December 31, 2015. ... Full year adjusted total revenues of $9.45 billion, up ... year; GAAP total revenues of $9.43 billion. Excluding the ... markets specialty and branded generics business (the "EPD Business"), ...
(Date:2/10/2016)... , Feb. 10, 2016  Resolve Therapeutics, ... transformative new approaches to the treatment of lupus ... of a multiple ascending dose study in patients ... compound RSLV-132. --> ... placebo-controlled multiple ascending dose study of RSLV-132 in ...
(Date:2/10/2016)... , Feb. 10, 2016  Rich Pharmaceuticals, Inc. (OTC ... a 1-for-100 reverse split of its issued and outstanding ... trading on Thursday, February 11, 2016. The Company,s common ... CUSIP number 76303T308 and temporary ticker symbol "RCHAD". After ... under the ticker symbol (RCHA).  --> ...
Breaking Medicine Technology:
(Date:2/10/2016)... ... February 10, 2016 , ... LaserShip, a regional parcel carrier that services the ... Eastern Michigan last Friday in order to aid in the Flint water crisis. In ... a facility located in Clio, only 15 miles away from Flint. , “We have ...
(Date:2/10/2016)... ... February 10, 2016 , ... InDemand ... within Healthcare, recently partnered with Heart City Health Center to improve ... 23 years, Heart City Health Center has provided the Elkhart community with access ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... 10 ... Brand. There were three leading bottled water brand owners that topped the list as ... enhance connectivity and optimize conversion. The premier brand was Tibet 5100, a top notch ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... welcomes S.S. Nesbitt as the latest addition to its growing list of Partner ... locations throughout the Southeast, from Orlando to Huntsville and in between. , Harnessing ...
(Date:2/10/2016)... ... February 10, 2016 , ... Pediatric therapists are challenged to ... shows that the Goal Attainment Scale (GAS) captures 20% more change in outcomes ... more about the Goal Attainment Scale, Education Resources Inc. is offering a course ...
Breaking Medicine News(10 mins):